Composition
Each tablet contains:
Ramipril ............................................................................................ 1.25 mg, 2.5 mg, 5 mg or 10 mg
Inactive ingredients:
Rampecardin 1.25 mg and 10 mg Tablets: Microcrystalline cellulose, starch 1500, sodium stearyl fumarate.
Rampecardin 2.5 mg Tablets: Microcrystalline cellulose, starch 1500, iron oxide yellow, sodium stearyl fumarate.
Rampecardin 5 mg Tablets: Microcrystalline cellulose, starch 1500, iron oxide red, sodium stearyl fumarate.

Therapeutic Indications
Treatment of hypertension.
Cardiovascular prevention:
Reduction of cardiovascular morbidity and mortality in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease).
diabetes with at least one cardiovascular risk factor.
Treatment of renal disease:
Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria.
Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor.
Manifest glomerular non-diabetic nephropathy as defined by macroproteinuria < 3 g/day.
Treatment of symptomatic heart failure.
Secondary prevention after acute myocardial infarction:
Reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Dosage and Administration:
Oral use:
It is recommended that Rampecardin is taken each day at the same time of the day.
Rampecardin can be taken before, with or after meals, because food intake does not modify its bioavailability. Rampecardin has to be swallowed with liquid. It must not be chewed or crushed.
Adults:
Diuretic-treated patients:
Hypotension may occur following initiation of therapy with Rampecardin; this is more likely in patients who are being treated concurrently with diuretics.
Caution is therefore recommended since these patients may be volume and/or salt depleted.
If possible, the diuretic should be discontinued 2-3 days before beginning therapy with Rampecardin.
In hypertensive patients in whom the diuretic is not discontinued, therapy with Rampecardin should be initiated with a 1.25 mg dose. Renal function and serum potassium should be monitored. The subsequent dosage of Rampecardin should be adjusted according to blood pressure target.